Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination

BACKGROUND:. The U.S. Food and Drug Administration has to date granted approval or emergency use authorization to three vaccines against severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. In clinical trials and real-use observational studies, the Pfizer-BioNTech BNT162b2 m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Benjamin Kahn, BA, Sokratis A. Apostolidis, MD, Vatsal Bhatt, MD, Allison R. Greenplate, PhD, Staci Kallish, DO, Anthony LaCava, MD, Alfredo Lucas, BA, Nuala J. Meyer, MD, MS, Dan Negoianu, MD, Alexis R. Ogdie, MD, MSCE, Michael G. S. Shashaty, MD, MSCE, Patricia A. Takach, MD, Leah Zuroff, MD, MS, E. John Wherry, PhD, George L. Anesi, MD, MSCE, MBE
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer 2021
Materias:	Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
Acceso en línea:	https://doaj.org/article/2bf181e5ca184060a76eb3a8b345f61c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2bf181e5ca184060a76eb3a8b345f61c
record_format	dspace
spelling	oai:doaj.org-article:2bf181e5ca184060a76eb3a8b345f61c2021-11-25T07:56:59ZMultisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination2639-802810.1097/CCE.0000000000000578https://doaj.org/article/2bf181e5ca184060a76eb3a8b345f61c2021-11-01T00:00:00Zhttp://journals.lww.com/10.1097/CCE.0000000000000578https://doaj.org/toc/2639-8028BACKGROUND:. The U.S. Food and Drug Administration has to date granted approval or emergency use authorization to three vaccines against severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. In clinical trials and real-use observational studies, the Pfizer-BioNTech BNT162b2 messenger RNA coronavirus disease 2019 vaccine, as well as the Moderna mRNA-1273 messenger RNA coronavirus disease 2019 vaccine, have demonstrated high efficacy and few adverse events. CASE SUMMARY:. A 20-year-old male college student in good health developed tinnitus and hematuria shortly after vaccination and progressed swiftly to a syndrome of: systemic inflammation; acute kidney injury requiring hemodialysis; acute, bilateral, complete sensorineural hearing loss; radiographic evidence of acute multifocal ischemic strokes; pericardial effusion complicated by tamponade physiology requiring pericardial evacuation; pleural effusions requiring evacuation; and systemic capillary leak. An extensive clinical and research investigation, including cytokine analysis, whole blood cytometry by time of flight, and whole exome sequencing, did not reveal a definitive explanatory mechanism. CONCLUSION:. While the overall safety profile of the BNT162b2 coronavirus disease 2019 vaccine remains excellent for the general population, rare serious events have been reported. In this report, we describe a case of multisystem inflammation and organ dysfunction of unknown mechanism beginning shortly after administration of the first dose of BNT162b2 coronavirus disease 2019 vaccine in a previously healthy recipient.Benjamin Kahn, BASokratis A. Apostolidis, MDVatsal Bhatt, MDAllison R. Greenplate, PhDStaci Kallish, DOAnthony LaCava, MDAlfredo Lucas, BANuala J. Meyer, MD, MSDan Negoianu, MDAlexis R. Ogdie, MD, MSCEMichael G. S. Shashaty, MD, MSCEPatricia A. Takach, MDLeah Zuroff, MD, MSE. John Wherry, PhDGeorge L. Anesi, MD, MSCE, MBEWolters KluwerarticleMedical emergencies. Critical care. Intensive care. First aidRC86-88.9ENCritical Care Explorations, Vol 3, Iss 11, p e0578 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
spellingShingle	Medical emergencies. Critical care. Intensive care. First aid RC86-88.9 Benjamin Kahn, BA Sokratis A. Apostolidis, MD Vatsal Bhatt, MD Allison R. Greenplate, PhD Staci Kallish, DO Anthony LaCava, MD Alfredo Lucas, BA Nuala J. Meyer, MD, MS Dan Negoianu, MD Alexis R. Ogdie, MD, MSCE Michael G. S. Shashaty, MD, MSCE Patricia A. Takach, MD Leah Zuroff, MD, MS E. John Wherry, PhD George L. Anesi, MD, MSCE, MBE Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
description	BACKGROUND:. The U.S. Food and Drug Administration has to date granted approval or emergency use authorization to three vaccines against severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. In clinical trials and real-use observational studies, the Pfizer-BioNTech BNT162b2 messenger RNA coronavirus disease 2019 vaccine, as well as the Moderna mRNA-1273 messenger RNA coronavirus disease 2019 vaccine, have demonstrated high efficacy and few adverse events. CASE SUMMARY:. A 20-year-old male college student in good health developed tinnitus and hematuria shortly after vaccination and progressed swiftly to a syndrome of: systemic inflammation; acute kidney injury requiring hemodialysis; acute, bilateral, complete sensorineural hearing loss; radiographic evidence of acute multifocal ischemic strokes; pericardial effusion complicated by tamponade physiology requiring pericardial evacuation; pleural effusions requiring evacuation; and systemic capillary leak. An extensive clinical and research investigation, including cytokine analysis, whole blood cytometry by time of flight, and whole exome sequencing, did not reveal a definitive explanatory mechanism. CONCLUSION:. While the overall safety profile of the BNT162b2 coronavirus disease 2019 vaccine remains excellent for the general population, rare serious events have been reported. In this report, we describe a case of multisystem inflammation and organ dysfunction of unknown mechanism beginning shortly after administration of the first dose of BNT162b2 coronavirus disease 2019 vaccine in a previously healthy recipient.
format	article
author	Benjamin Kahn, BA Sokratis A. Apostolidis, MD Vatsal Bhatt, MD Allison R. Greenplate, PhD Staci Kallish, DO Anthony LaCava, MD Alfredo Lucas, BA Nuala J. Meyer, MD, MS Dan Negoianu, MD Alexis R. Ogdie, MD, MSCE Michael G. S. Shashaty, MD, MSCE Patricia A. Takach, MD Leah Zuroff, MD, MS E. John Wherry, PhD George L. Anesi, MD, MSCE, MBE
author_facet	Benjamin Kahn, BA Sokratis A. Apostolidis, MD Vatsal Bhatt, MD Allison R. Greenplate, PhD Staci Kallish, DO Anthony LaCava, MD Alfredo Lucas, BA Nuala J. Meyer, MD, MS Dan Negoianu, MD Alexis R. Ogdie, MD, MSCE Michael G. S. Shashaty, MD, MSCE Patricia A. Takach, MD Leah Zuroff, MD, MS E. John Wherry, PhD George L. Anesi, MD, MSCE, MBE
author_sort	Benjamin Kahn, BA
title	Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
title_short	Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
title_full	Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
title_fullStr	Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
title_full_unstemmed	Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
title_sort	multisystem inflammation and organ dysfunction after bnt162b2 messenger rna coronavirus disease 2019 vaccination
publisher	Wolters Kluwer
publishDate	2021
url	https://doaj.org/article/2bf181e5ca184060a76eb3a8b345f61c
work_keys_str_mv	AT benjaminkahnba multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT sokratisaapostolidismd multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT vatsalbhattmd multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT allisonrgreenplatephd multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT stacikallishdo multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT anthonylacavamd multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT alfredolucasba multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT nualajmeyermdms multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT dannegoianumd multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT alexisrogdiemdmsce multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT michaelgsshashatymdmsce multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT patriciaatakachmd multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT leahzuroffmdms multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT ejohnwherryphd multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination AT georgelanesimdmscembe multisysteminflammationandorgandysfunctionafterbnt162b2messengerrnacoronavirusdisease2019vaccination
_version_	1718413607984693248

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination

Ejemplares similares